ClinicalTrials.gg
RecruitingNCT07800364TizanidineUpdated Sep 2, 2026

The Effect of Preoperative Administration of Oral Tizanidine on the Postoperative Pain and Sleep Quality

An interventional study of Tizanidine and Placebo in The Effect of Preoperative Administration of Oral Tizanidine and Post Operative Pain, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Tanta University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Mar 2026, registered Aug 2026).
  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Pain, Postoperative by Tanta University — 7 open to participants now, 8 under way, 1 of them phase 3. Pain, Postoperative · Tanta University.

Planned enrollment
20th of 38
68 · median 69
Started
2026
with 4 others
No phase
36 of 38
7 open now
Registered
37th of 38
by date

Among the 38 studies in Pain, Postoperative by Tanta University, this one is the 20th largest by planned enrollment, is one of 5 that started in 2026, is one of 36 with no phase, and was the 37th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

7 of the 38 studies in Pain, Postoperative by Tanta University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Pain, Postoperative by Tanta University, or all of them as a file.
02

Study summary

The majority of lower limb fractures treated with surgery often leading to significant morbidity and mortality. Despite improvements in perioperative care, about 20% suffer from severe postoperative complications. So, effective perioperative pain management is crucial in this demographic to ensure optimal recovery and reduce complications. (1) Controlling the postoperative pain often begins in recovery room by using opioids, especially morphine. However, systemic opioids may develop many complications such as nausea and vomiting, apnea, respiratory depression, and urinary retention. To reduce the complications and consumption of the opioids, other procedures are recommended. One of these procedures is preemptive analgesia(2).

In addition to pain, disrupted sleep quality is a common challenge, with evidence suggesting a bidirectional relationship where poor sleep exacerbates pain, and pain further disrupts sleep (3). Addressing both pain and sleep disturbances in the perioperative period is therefore critical for enhancing recovery and improving overall patient outcomes

03

Conditions studied

  • The Effect of Preoperative Administration of Oral Tizanidine
  • Post Operative Pain

Keywords

  • Preoperative, Tizanidine,
  • Pain
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥ 21 years

    • Scheduled for lower limb orthopedic surgery
    • Able to provide

Exclusion criteria

Exclusion Criteria:

  • History of to tizanidine

    • Pregnancy or breastfeeding
    • Failure of spinal anesthesia or inadequate block.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    tizanidine group

    tizanidine

    Drug: Tizanidine

  • Placebo comparator
    placebo group

    placebo

    Drug: Placebo

Interventions

  • oral administered preoperatively

  • DrugPlacebo

    oral placebo adminstered preoperatively

06

What researchers measure

Primary outcomes

  1. Time to first request of rescue analgesia

    Time frame: 24 hr

  2. opioid consumption in 48 hrs postoperatively

    Time frame: 48hr

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Sep 2026, 6 months after the start.

Of 2,097 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 6 months is below that.

Counting every sponsor, half of 2,110 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2026
First posted
Sep 2, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07800364
Lead sponsor
Tanta University
Responsible party
Marwa Ahmed Abogabal (Marwa Ahmed Abogabal, Tanta University) — Principal investigator
First posted
Sep 2, 2026
Start date
Mar 1, 2026
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Sep 2, 2026

Study contacts

Marwa Abogabal, Assistant professor
Contact
Dr_mora1985@med.tanta.edu.eg
0201004190210

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tizanidine

Start the discussion